Physician profile
Peter C Wu
NPI 1326143322
$21,758.83
in general payments reported to CMS, 2019-2025
48 companies · $2,605 in 2025
The $2,605 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,520 · 2020: $3,038 · 2021: $4,290 · 2022: $3,866 · 2023: $3,211 · 2024: $2,229 · 2025: $2,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,044.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,257.56 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $1,970.37 | 2019-2024 | Xarelto |
| Abbvie INC. | $1,769.32 | 2019-2025 | Linzess, Viberzi, Creon |
| Lilly USA, LLC | $1,604.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,559.65 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,393.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Nestle Healthcare Nutrition INC. | $1,324.46 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,171.10 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $965.49 | 2020-2025 | Livalo, Seglentis, Zoryve |
| Amgen INC. | $754.33 | 2019-2025 | Otezla, Repatha, Repatha |
| Aimmune Therapeutics, INC. | $681.10 | 2024-2025 | Zenpep |
| Bayer Healthcare Pharmaceuticals INC. | $658.54 | 2021-2025 | |
| Amarin Pharma, INC. | $640.53 | 2019-2022 | |
| Gilead Sciences, INC. | $541.95 | 2019-2024 | |
| Astellas Pharma US INC | $531.92 | 2019-2025 | Veozah |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.